Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

101. Rheumatoid arthritis Full Text available with Trip Pro

Rheumatoid arthritis Rheumatoid arthritis - NICE CKS Share Rheumatoid arthritis: Summary Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. RA typically presents as inflammatory arthritis affecting the small joints of the hands and the feet (usually both sides equally and symmetrically) although any synovial joint can be involved. As RA progresses, any system of the body may be affected, leading to an increased risk of premature death. RA is associated with a number (...) and Care Excellence (NICE) guidelines Rheumatoid arthritis in adults: management [ ], Rheumatoid arthritis: national clinical guideline for management and treatment in adults [ ], the American College of Rheumatology (ACR) Guideline for the treatment of rheumatoid arthritis [ ], the European League Against Rheumatism (EULAR) 2016 update of the EULAR recommendations for the management of early arthritis [ ], the British Medical Journal (BMJ) best practice guide Rheumatoid Arthritis [ ], expert opinion

2019 NICE Clinical Knowledge Summaries

102. Does diet or dietary supplements reduce disease activity in rheumatoid arthritis? A systematic review of randomized controlled trials

Does diet or dietary supplements reduce disease activity in rheumatoid arthritis? A systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

103. Examining the relationship between rheumatoid arthritis, multimorbidity and adverse health-related outcomes: a systematic review

Examining the relationship between rheumatoid arthritis, multimorbidity and adverse health-related outcomes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

104. Linked total elbow arthroplasty for rheumatoid arthritis of the elbow joint: a systematic review of functional outcomes

Linked total elbow arthroplasty for rheumatoid arthritis of the elbow joint: a systematic review of functional outcomes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

105. JAK inhibitor monotherapy versus combination therapy of JAK inhibitors with methotrexate on treatment response rate and joint functionality in patients with rheumatoid arthritis- a systematic review and meta-analysis

JAK inhibitor monotherapy versus combination therapy of JAK inhibitors with methotrexate on treatment response rate and joint functionality in patients with rheumatoid arthritis- a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete

2019 PROSPERO

106. Relationship between dietary intake, health and health related quality of life in children and adolescents with rheumatoid arthritis: a systematic review

Relationship between dietary intake, health and health related quality of life in children and adolescents with rheumatoid arthritis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

107. Baricitinib for rheumatoid arthritis [Cochrane protocol]

Baricitinib for rheumatoid arthritis [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

108. Accuracy of digital X-ray (DXR) evaluation on hand bone loss (HBL) for diagnosis of rheumatoid arthritis (RA): a systematic review protocol

Accuracy of digital X-ray (DXR) evaluation on hand bone loss (HBL) for diagnosis of rheumatoid arthritis (RA): a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

109. Methodological approaches to assess adherence to disease modifying antirheumatic drugs among rheumatoid arthritis patients in administrative healthcare databases: systematic review and meta-analysis

Methodological approaches to assess adherence to disease modifying antirheumatic drugs among rheumatoid arthritis patients in administrative healthcare databases: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

110. Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis' disease activity indicators: a systematic review and meta-analysis

Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis' disease activity indicators: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

111. Baricitinib (Olumiant) - moderate to severe rheumatoid arthritis (RA)

Baricitinib (Olumiant) - moderate to severe rheumatoid arthritis (RA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after

2019 Health Canada - Drug and Health Product Register

112. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study Full Text available with Trip Pro

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double (...) -blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12

2019 EvidenceUpdates

113. The relationship between functional social support and depression in adults with rheumatoid arthritis: a systematic review and meta-analysis

The relationship between functional social support and depression in adults with rheumatoid arthritis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

114. Impact of interleukin-6 receptor inhibitors in patients with rheumatoid arthritis on blood system disorders: a meta-analysis of randomized trials

Impact of interleukin-6 receptor inhibitors in patients with rheumatoid arthritis on blood system disorders: a meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

115. Minimal clinically important differences (MCIDs) of measurement instruments in rheumatoid arthritis: a systematic review

Minimal clinically important differences (MCIDs) of measurement instruments in rheumatoid arthritis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

116. Dimethylarginine as an indicator of cardiovascular disease in rheumatoid arthritis patients: a systematic review and meta-analysis

Dimethylarginine as an indicator of cardiovascular disease in rheumatoid arthritis patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

117. Telehealth effects in literacy and self-care in people with rheumatoid arthritis: a protocol of systematic review and meta-analysis

Telehealth effects in literacy and self-care in people with rheumatoid arthritis: a protocol of systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

118. Survivin in rheumatoid arthritis, a considerable prognostic and diagnostic biomarker: a systematic review

Survivin in rheumatoid arthritis, a considerable prognostic and diagnostic biomarker: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

119. Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial (Abstract)

Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial To evaluate the efficacy of dry heat treatment (fluidotherapy) in improving hand function in patients with rheumatoid arthritis.Prospective randomized controlled trial.Departments of Physical Medicine and Rehabilitation and Rheumatology in a university hospital.Patients with rheumatoid arthritis.All patients were randomly divided into two groups. Group (...)  = 0.039).Dry heat treatment (fluidotherapy) was not effective in improving hand function in patients with rheumatoid arthritis. Moreover, no positive effect on any other clinical parameters was observed.

2018 EvidenceUpdates

120. Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V

Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sarilumab (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-39 (...) Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-39 Version 1.0 Sarilumab (rheumatoid arthritis) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)